Untitled design (77).png 1

Curve Therapeutics

Drug Discovery

Membership category
Emerging Y3

School of Chemistry, Building 30, University Road, Southampton, SO17 1BJ, United Kingdom

Curve Therapeutics at a glance

Small-molecule drug discovery platform based on functional library screening inside mammalian cells to identify first- and best-in-class therapeutics

About Curve Therapeutics

Curve’s mission is to transform the discovery of first-in-class small molecule therapeutics by broadening the landscape of disease targets that can be drugged. The company’s Microcycle® platform enables direct screening for biologically active hits inside mammalian cells and creates a toolkit for hit-to-lead programmes. Curve is deploying this innovative platform to build a pipeline of first-in-class small molecules to address high priority, therapeutically relevant cancer targets. Curve’s proprietary platform is built on pioneering research by the Tavassoli lab and described in more than 30 peer-reviewed publications covering a wide range of protein-protein interactions over a 15-year period. The central components of the Microcycle screening platform are protected through international patents and patent applications and exclusively licensed to Curve.

Therapeutic area(s)

Articles Curve Therapeutics has contributed to